Bookmark and Share

$VTGN Featured in Research Report

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent research report by Aegis Capital Corp. The report reads, “VistaGen is developing multiple therapeutic candidates for the treatment of anxiety, depression, and other CNS indications. VistaGen’s development pipeline includes PH94B, a neuroactive nasal spray targeting Social Anxiety Disorder (‘SAD’), among other conditions, PH10, an additional neuroactive nasal spray for indications including Major Depressive Disorder (‘MDD’), and AV-101 an oral drug for psychiatric and other CNS disorders. We believe Phase 2 data in PH94B and PH10 strongly supports proof of concept, including compelling safety and efficacy data that likely differentiate these assets from existing treatments in crucial ways that could be supportive of market adoption if and when approved.”

To view the full report, visit http://ibn.fm/eLamD

About VistaGen Therapeutics

VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, October 8th, 2020 Uncategorized